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In addition to the fungal cellular membrane, the cellular antioxidant system can also be
a viable target in the antifungal action of amphotericin B (AMB). Co-application of certain
redox-potent natural compounds with AMB actually increases efficacy of the drug through
chemosensitization. Some redox-potent chemosensitizers and AMB perturb common cellu-
lar targets, resulting in synergistic inhibition of fungal growth. Chemosensitizing activities of
four redox-potent benzaldehydes were tested against clinical and reference strains of Can-
dida albicans, C. krusei, C. tropicalis, and Cryptococcus neoformans in combination with
AMB, based on assays outlined by the European Committee on Antimicrobial Susceptibility
Testing.Two dihydroxybenzaldehydes (DHBAs), i.e., 2,3-DHBA and 2,5-DHBA, significantly
enhanced activity of AMB against most strains, as measured by lower minimum inhibitory
concentrations and/or minimum fungicidal concentrations (MFCs). A non-hydroxylated ben-
zaldehyde, trans-cinnamaldehyde, showed chemosensitizing activity through lower MFCs,
only. Contrastingly, a methoxylated benzaldehyde (3,5-dimethoxybenzaldehyde) had no
chemosensitizing activity, as all strains were hypertolerant to this compound. Bioassays
using deletion mutants of the model yeast, Saccharomyces cerevisiae, indicated DHBAs
exerted their chemosensitizing activity by targeting mitochondrial superoxide dismutase.
This targeting, in turn, disrupted the ability of the yeast strains to respond to AMB-induced
oxidative stress. These in vitro results indicate that certain DHBAs are potent chemosen-
sitizing agents to AMB through co-disruption of the oxidative stress response capacity of
yeasts. Such redox-potent compounds show promise for enhancing AMB-based antifungal
therapy for candidiasis and cryptococcosis.
Keywords: amphotericin B, dihydroxybenzaldehydes, chemosensitization, Candida, Cryptococcus, antioxidant
system, superoxide dismutase
INTRODUCTION
There has been a persistent effort to improve efficacy of conven-
tional antimycotic drugs, especially for treatment of human can-
didiasis and cryptococcosis. Currently, liposomal amphotericin
B (LAMB), AMB lipid complex, etc., are preferred for clinical
therapy of these mycoses, in that conventional AMB (e.g., AMB
deoxycholate) is hepatotoxic/nephrotoxic (Patel et al., 2011). The
lipid-based AMBs are generally recommended for patients who
Abbreviations: AMB, amphotericin B; CFU, colony forming unit;
Cinn, cinnamaldehyde; DHBA, dihydroxybenzaldehyde; 2,3-DHBA, 2,3-
dihydroxybenzaldehyde; 2,5-DHBA, 2,5-dihydroxybenzaldehyde; 3,5-DMBA,
3,5-dimethoxybenzaldehyde; DMSO, dimethyl sulfoxide; EUCAST, European
Committee on Antimicrobial Susceptibility Testing; FFCI, fractional fungicidal
concentration indices; FICI, fractional inhibitory concentration indices; Glr1,
glutathione reductase; Gsh1, γ-glutamylcysteine synthetase; LAMB, liposomal
amphotericin B; MFC, minimum fungicidal concentration; MIC, minimum
inhibitory concentration; Mn-SOD, mitochondrial superoxide dismutase; SG,
synthetic glucose; Sod, superoxide dismutase; Sod1, cytosolic superoxide dismutase;
Sod2, mitochondrial superoxide dismutase; Trx2, thioredoxin; WT, wild type; Ycf1,
glutathione S-conjugate pump.
are intolerant to conventional AMB, which is still administered for
treatment of mycoses, such as pediatric fungal infections (Allen,
2010 and references therein). However, high doses of LAMBs
cause nephrosis and other tissue-damage in murine models of
invasive pulmonary aspergillosis (Clemons et al., 2011). Thus, an
antifungal therapeutic strategy to reduce side effects of AMB is
warranted.
Amphotericin B binds to ergosterol in the fungal plasma mem-
brane, undermining cell membrane integrity and causing ion
leakage. However, formation of channels in the fungal membrane
is not the sole mode of action of AMB (Palacios et al., 2007).
There is ample literature showing AMB induces oxidative damage
to both ascomycete and zygomycete fungal cells (Sokol-Anderson
et al., 1986; Graybill et al., 1997, and references therein; Okamoto
et al., 2004; An et al., 2009; González-Párraga et al., 2011). For
example, Aspergillus terreus, a causative agent of human invasive
aspergillosis, is intrinsically resistant to AMB, compared to other
aspergilli. This resistance was thought to result from lower mem-
brane ergosterol, thus offering fewer target sites for AMB (Walsh
et al., 2003). However, this resistance was later found to result from
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higher catalase activity, an enzyme that protects against oxida-
tive stress. This latter finding indicated there is an alternate or
additional mode of action of AMB by causing oxidative damage
(Blum et al., 2008). This was further confirmed by the finding
that superoxide radical-mediated oxidative damage was caused by
AMB activity (Okamoto et al., 2004).
Disrupting fungal redox homeostasis and/or the antioxidant
system should augment antimycotic activity of AMB. Moreover,
the antioxidant system plays an important role in pathogen vir-
ulence and defense against host cellular oxidative burst during
infection (Washburn et al., 1987; Hamilton and Holdom, 1999; de
Dios et al., 2010). Such disruption of the fungal redox home-
ostasis/antioxidant system could employ redox-potent natural
products or their analogs (Jacob, 2006). The natural phenolic 2,3-
dihydroxybenzaldehyde (2,3-DHBA) augments antifungal activity
of a number of fungicidal agents by interfering with the fun-
gal oxidative stress response system (Kim et al., 2008, 2011). In
view that both 2,3-DHBA and AMB stress the fungal antioxidant
system, their co-application should result in elevated antifungal
activity.
The aim of this study was to test the concept of using benzalde-
hydes, such as 2,3-DHBA and some of its structural derivatives, as
chemosensitizing agents to AMB. As a proof-of-concept, we used
clinical strains and species of Candida and Cryptococcus neofor-
mans for this test. Specifically, we compared the chemosensitizing
activity between two hydroxylated DHBAs (2,3- or 2,5-DHBA)
and two non-hydroxylated benzaldehydes [non-DHBAs; trans-
cinnamaldehyde or 3,5-dimethoxybenzaldehyde (3,5-DMBA)].
We reasoned that use of chemosensitizing agents from natural
sources could enhance the activity of AMB, while lowering toxic
side effects of this drug to human cells.
MATERIALS AND METHODS
FUNGAL STRAINS AND CULTURE CONDITIONS
Candida albicans 90028 and C. krusei 6258 were procured from
American Type Culture Collection (Manassas, VA, USA). C. albi-
cans CAN276, C. krusei CAN75, C. tropicalis CAN286 and C.
neoformans CN24 were procured from Instituto de Higiene e
Medicina Tropical/CREM, Universidade nova de Lisboa, Portu-
gal. Saccharomyces cerevisiae wild type (WT) BY4741 (Mat a
his3∆1 leu2∆0 met15∆0 ura3∆0) and selected single gene dele-
tion mutants (see text) were procured from Open Biosystems
(Huntsville, AL, USA). Yeast strains were cultured on Synthetic
Glucose (SG; Yeast nitrogen base without amino acids 0.67%,
glucose 2% with appropriate supplements: uracil 0.02 mg mL−1,
amino acids 0.03 mg mL−1) or yeast peptone dextrose (YPD; Bacto
yeast extract 1%, Bacto peptone 2%, glucose 2%) agar at 30˚C for
S. cerevisiae or 35˚C for yeast pathogens (Candida, Cryptococcus),
respectively.
ANTIFUNGAL DRUGS AND COMPOUNDS
Amphotericin B,diamide,2,3- or 2,5-DHBA, trans-cinnamaldehyde,
and 3,5-DMBA were procured from Sigma Co. (St. Louis, MO,
USA). Each compound was dissolved in dimethyl sulfoxide
(DMSO; absolute DMSO amount:<2% in medium) before incor-
poration into the culture medium. In all tests, control plates (i.e.,
“No treatment”) contained DMSO at levels equivalent to that
of cohorts receiving antifungal agents, within the same set of
experiments.
SUSCEPTIBILITY TESTING: PLATE (AGAR) BIOASSAY
Petri plate-based yeast dilution bioassays were performed on the
WT and antioxidant mutants of S. cerevisiae to assess the effects
of AMB (0.0, 0.5, 1.0, 1.5, and 2.0µg mL−1) on the fungal antiox-
idant system. These assays were performed in duplicate on SG
agar following previously described protocols (Kim et al., 2008).
Similar dilution bioassays were performed on Candida and Cryp-
tococcus to assess their differential sensitivity to AMB (0.0, 0.5,
1.0µg mL−1) or diamide (0.0, 0.2, 0.4, 0.6, 0.8 mM). Cell growth
was observed for 3–5 days.
SUSCEPTIBILITY TESTING: MICROTITER (LIQUID) BIOASSAY
To determine changes in antifungal minimum inhibitory con-
centrations (MICs), i.e., differences/changes in MICs of each
compound (AMB, benzaldehydes) alone as compared to when
they were combined, triplicate assays were performed using
broth microdilution protocols according to methods outlined by
the European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST; Arendrup et al., 2012; definitive document EDef
7.2.). MIC was defined as the concentration at which no fungal
growth was visible. These assays were performed using a range
of concentrations of test compounds, as follows: AMB – 0.0, 1.0,
2.0, 4.0, 8.0, 16.0, 32.0µg mL−1; 2,3-DHBA, 2,5-DHBA, trans-
cinnamaldehyde, 3,5-DMBA – 0.0, 0.00625, 0.0125, 0.025, 0.05,
0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 mM.
To measure changes in minimum fungicidal concentrations
(MFCs), i.e., differences/changes of MFCs of each compound
(AMB, benzaldehydes) alone compared to when they were com-
bined, the entire volume of each microtiter well (200µL), after
determination of MICs,was spread onto individualYPD plates and
cultured an additional 48 h (72 h for C. neoformans). The lowest
concentration of agent showing≥99.9% fungal death was defined
as the MFC, except where noted (see tables). Student’s t -test for
paired data was used to determine significant differences between
means of MICs or MFCs of each compound when combined
(i.e., chemosensitization) vs alone (i.e., no chemosensitization)
for six yeast pathogens (calculation was based on Kirkman, 1996).
Compound interactions [for both fractional inhibitory concentra-
tion indices (FICI) and fractional fungicidal concentration indices
(FFCI)] were calculated based on: FICI or FFCI= (MIC or MFC
of compound A in combination with compound B/MIC or MFC
of compound A, alone)+ (MIC or MFC of compound B in com-
bination with compound A/MIC or MFC of compound B, alone).
FICI or FFCI was defined as: “synergistic” (FICI or FFCI ≤0.5) or
“indifferent” (FICI or FFCI >0.5–4; Odds, 2003).
RESULTS
We tested the hypothesis that benzaldehydes could act as
chemosensitizing agents to AMB against clinical strains and
species of Candida and C. neoformans. First, Petri plate-based
yeast dilution bioassays were used to evaluate any relationship
between AMB-sensitivity and lower antioxidant capacity. Dupli-
cate assays were performed on SG agar containing AMB (0.0, 0.5,
and 1.0µg mL−1) according to described protocols (Kim et al.,
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2008). In this test, C. albicans CAN276 was the most sensitive of
all strains when exposed up to 1.0µg mL−1 AMB (Figure 1). Next,
we examined the effect of diamide (0.0, 0.2, 0.4, 0.6, and 0.8 mM)
on these strains. Diamide causes stoichiometric oxidative stress
by depleting cellular thiols, such as glutathione. CAN276 was also
the most sensitive of Candida species or strains to diamide (up to
0.8 mM; Figure 1). C. krusei 6258, C. krusei CAN75, and C. tropi-
calis CAN286 grew similar to control (no diamide) cohorts (i.e., no
antifungal activity against these strains at the given concentration).
C. albicans 90028 and C. neoformans CN24 showed slight sensi-
tivity to diamide, >100-fold less than CAN276 (Figure 1). The
high sensitivity of CAN276 to both AMB and diamide indicated
a diminished oxidative stress response system increases sensitivity
to AMB.
Identification of target(s) of AMB within the yeast antioxi-
dant system was attempted using deletion mutants of the model
fungus, S. cerevisiae. Petri plate-based cell-dilution bioassays on
SG agar with AMB (0.0, 0.5, 1.0, 1.5, and 2.0µg mL−1; in dupli-
cate) included the WT and four antioxidant mutant strains,
as follows: (1) yap1∆ [Yap1p is the transcription factor regu-
lating expression of four downstream genes within the oxida-
tive stress response pathway, i.e., GLR1 (glutathione reductase),
YCF1 (a glutathione S-conjugate pump), TRX2 (thioredoxin),
and GSH1 (γ-glutamylcysteine synthetase; Fernandes et al., 1997;
Lee et al., 1999)]; (2) sod1∆ (cytosolic superoxide dismutase);
(3) sod2∆ (mitochondrial superoxide dismutase, Mn-SOD); and
(4) glr1∆ (glutathione reductase; see Saccharomyces Genome
Database; www.yeastgenome.org, accessed May 22, 2012). These
representative mutants were selected because: (1) they play key
roles in maintaining cellular redox homeostasis in both enzy-
matic (e.g., superoxide radical-scavenging) and non-enzymatic
(e.g., glutathione homeostasis) aspects; (2) among 45 S. cerevisiae
antioxidant/stress response system mutants examined, tolerance
to redox-potent benzo analogs relied upon Mn-SOD (SOD2) or
glutathione reductase (GLR1; Kim et al., 2008); and (3) oxida-
tive damage from AMB in C. albicans is induced by superoxide
(Okamoto et al., 2004). Of the four deletion mutants, only sod2∆
was hypersensitive to AMB (up to 2.0µg mL−1; Figure 2). These
results showed Mn-SOD plays a relatively greater role in fungal tol-
erance to AMB-induced toxicity than the other genes represented,
similar to that found for treatment by redox-potent 2,3-DHBA
(Kim et al., 2008).
The capacity of benzaldehyde analogs (DHBAs and non-
DHBAs) to influence antifungal activity of AMB was examined
using triplicate checkerboard microdilution bioassays according
to the EUCAST (see Materials and Methods). The four benzalde-
hydes tested were 2,3- and 2,5-DHBAs, trans-cinnamaldehyde,
and 3,5-DMBA. All four of these compounds targeted Mn-
SOD in S. cerevisiae (Kim et al., 2008, 2011). In prior studies,
2,3-DHBA and cinnamaldehyde exhibited the highest antifun-
gal activity against S. cerevisiae or filamentous fungi, respec-
tively, when treated alone: S. cerevisiae- 2,3-DHBA (MIC
0.08 mM) >2,5-DHBA (MIC 1.8 mM) or filamentous fungi-
cinnamaldehyde (MIC 0.58 mM) >3,5-DMBA (MIC 1.17 mM;
Kim et al., 2008, 2011). In the present study, the DHBAs
had the most potent chemosensitizing activity to AMB (see
Tables 1 and 2).
FIGURE 1 | Dilution bioassays showing phenotypic responses of yeast
pathogens to amphotericin B (AMB) or diamide. 1×106 cells were
serially diluted 10-fold in SG liquid medium, and were inoculated onto
agar plates. Data are representative results shown from 1µg mL−1 (AMB)
and 0.8 mM (diamide), respectively.
FIGURE 2 | Dilution bioassay showing phenotypic responses of
S. cerevisiae strains to amphotericin B (AMB). S. cerevisiae sod2∆
[mitochondrial superoxide dismutase (Mn-SOD) gene deletion] mutant
exhibited increased sensitivity to AMB over that of other deletion mutants
(yap1∆, sod1∆, and glr1∆) involving antioxidation responses. Data are
representative results shown from 2µg mL−1 (AMB). 1×106 cells were
serially diluted 10-fold in SG liquid medium, and were inoculated onto agar
plates.
As an example of DHBA-AMB interactions, the MIC for AMB
(MICAMB), alone, for C. albicans 90028 was 2µg mL−1 (Tables 1
and 2). However, the MICAMB was lowered to <1µg mL−1
with either of the DHBAs. MICs of the DHBAs were concomi-
tantly lowered in these co-applications, as well. MFCs were sim-
ilarly affected, where the MFC of AMB alone (4µg mL−1) was
reduced to <1µg mL−1 by co-treatment with DHBAs. The rel-
atively higher sensitivity of CAN276 than C. albicans 90028 to
AMB (see Figure 1) was also reflected in MFC values; MFCAMB
CAN276= 2µg mL−1, MFCAMB C. albicans 90028= 4µg mL−1
(Tables 1 and 2; See also Figure 3). The range of MICs of
2,3-DHBA (0.4–0.8 mM) was lower than that of 2,5-DHBA (1.6–
3.2 mM) in all yeasts tested (Tables 1 and 2). Thus, the higher to
lower antifungal activity of 2,3-DHBA >2,5-DHBA in these yeast
pathogens reflected that of S. cerevisiae (Kim et al., 2008; see also
above).
The non-DHBAs tested were not potent chemosensitizing
agents for AMB against the yeasts, as compared with the DHBAs.
Interactions of cinnamaldehyde co-applied with AMB, in C. albi-
cans 90028, CAN276, C. krusei 6258, and C. neoformans CN24,
were “indifferent,” although this co-application showed certain
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Table 1 | Chemosensitization of AMB by 2,3-DHBA*.
Strains Compounds MIC alone MIC combined FICI MFC alone MFC combined FFCI
C. albicans 2,3-DHBA 0.4 0.2 1.0 6.4 0.8 0.4
ATCC 90028 AMB 2 1 4 1
C. albicans 2,3-DHBA 0.4 0.0125 0.5 3.2 0.4 0.6
CAN276 AMB 2 1 2 1
C. krusei 2,3-DHBA 0.8 0.2 0.8 6.4 3.2 1.0
ATCC 6258 AMB 2 1 2 1
C. krusei 2,3-DHBA 0.8 0.4 1.0 6.4 3.2 0.8
CAN75 AMB 2 1 4 1
C. tropicalis 2,3-DHBA 0.8 0.2 0.8 3.2 1.6 0.8
CAN286 AMB 2 1 4 1
C. neoformans 2,3-DHBA 0.8 0.4 1.0 3.2 0.1 0.5
CN24 AMB 4 2 4 2
t -Test 2,3-DHBA P <0.005 P <0.01
AMB P <0.05 P <0.005
MFCs are concentrations where ≥99.9% fungal death was achieved. Synergistic interactions are in bold (see Materials and Methods for calculations).
*2,3-DHBA, 2,3-dihydroxybenzaldehyde (mM); AMB, amphotericin B (µgmL−1); MIC, minimum inhibitory concentration; MFC, minimum fungicidal concentration;
FICI, fractional inhibitory concentration indices; FFCI, fractional fungicidal concentration indices.
Table 2 | Chemosensitization of AMB by 2,5-DHBA*.
Strains Compounds MIC alone MIC combined FICI MFC alone MFC combined FFCI
C. albicans 2,5-DHBA 1.6 0.8 1.0 6.4 3.2 0.8
ATCC 90028 AMB 2 1 4 1
C. albicans 2,5-DHBA 1.6 0.8 1.0 6.4 3.2 1.0
CAN276 AMB 2 1 2 1
C. krusei 2,5-DHBA 3.2 3.2 2.0 >6.4† 6.4 0.8
ATCC 6258 AMB 2 2 4 1
C. krusei 2,5-DHBA 3.2 0.0125 0.5 >6.4† 6.4 1.0
CAN75 AMB 4 2 4 2 (99.7% killing)
C. tropicalis 2,5-DHBA 3.2 1.6 1.0 >6.4† 3.2 0.8
CAN286 AMB 2 1 4 2
C. neoformans 2,5-DHBA 3.2 1.6 1.0 6.4 3.2 1.0
CN24 AMB 2 1 2 1
t -Test 2,5-DHBA P <0.05 P <0.01
AMB P <0.05 P <0.005
MFCs are concentrations where≥99.9% fungal death was achieved, except where noted in the table. Synergistic interactions are in bold (see Materials andMethods
for calculations).
*2,5-DHBA, 2,5-dihydroxybenzaldehyde (mM); AMB, amphotericin B (µgmL−1); MIC, minimum inhibitory concentration; MFC, minimum fungicidal concentration;
FICI, fractional inhibitory concentration indices; FFCI, fractional fungicidal concentration indices.
†Assays were conducted up to the highest concentration of 6.4mM. For calculation purposes, 12.8mM (doubling of 6.4mM) was used.
level of enhanced antifungal activity for MFCs (Table 3). More-
over, 3,5-DMBA did not show any antifungal activity in any of the
yeast strains, even at the highest concentration tested (6.4 mM),
nor any chemosensitization when co-applied with AMB (data not
shown). Contrastingly, 3,5-DMBA had potent antifungal activ-
ity (average MIC: 1.17 mM) against filamentous fungal pathogens
(i.e., species and strains of Aspergillus, Penicillium; Kim et al.,
2011). Perhaps yeast pathogens possess an intrinsic capacity to
detoxify 3,5-DMBA.
DISCUSSION
All compounds tested, except for 3,5-DMBA, are known nat-
ural volatiles or components of the essential oils of a number
of plants, including almond and vanilla. Both 2,3- and 2,5-
DHBAs and trans-cinnamaldehyde have been shown to have a
moderate level (MICs 20–80µg mL−1) of antibacterial activ-
ity (Wong et al., 2008). However, we found that the anti-
fungal activity of these compounds, alone, is not particularly
noteworthy.
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FIGURE 3 | Exemplary plate bioassay to determine minimum fungicidal
concentration (MFC) in C. albicans 90028 (a reference strain) and
CAN276 (a clinical isolate). In C. albicans 90028, co-application of AMB
(2.0µg mL−1) and cinnamaldehyde (0.8 mM) completely inhibited colony
survival, while survived colonies appeared under the independent treatment
of AMB or cinnamaldehyde. Similar assay was performed on C. albicans
CAN276, where no colonies appeared on 2.0µg mL−1 of AMB, confirming the
higher sensitivity of C. albicans CAN276 to AMB than C. albicans 90028.
Table 3 | Chemosensitization of AMB by cinnamaldehyde*.
Strains Compounds MIC alone MIC combined FICI MFC alone MFC combined FFCI
C. albicans Cinn 0.8 0.8 2.0 1.6 0.8 0.8
ATCC 90028 AMB 2 2 4 1
C. albicans Cinn 0.8 0.8 2.0 1.6 0.8 1.0
CAN276 AMB 2 2 2 1
C. krusei Cinn 0.8 0.8 2.0 1.6 0.8 1.0
ATCC 6258 AMB 4 4 4 (99.8% killing) 2
C. krusei Cinn 0.8 0.8 2.0 0.8 0.8 2.0
CAN75 AMB 4 4 4 4
C. tropicalis Cinn 1.6 1.6 2.0 1.6 1.6 2.0
CAN286 AMB 2 2 4 4
C. neoformans Cinn 0.8 0.8 2.0 0.8 0.4 1.0
CN24 AMB 4 4 4 2 (99.8% killing)
t -Test Cinn P -values: not determined
(neutral interaction)
P <0.1
AMB P <0.1
MFCs are concentrations where ≥99.9% fungal death was achieved, except where noted in the table.
*Cinn, cinnamaldehyde (mM); AMB, amphotericin B (µgmL−1); MIC, minimum inhibitory concentration; MFC, minimum fungicidal concentration; FICI, fractional
inhibitory concentration indices; FFCI, fractional fungicidal concentration indices.
However, as previously reported, certain phenolic antioxidants
can prolong the activity of AMB against C. albicans by stabi-
lizing the multiple double bonds of the polyene moiety. But,
the mechanism by which the combination of such phenolics
and AMB resulted in a synergistic interaction was unidentified
(Beggs et al., 1978). Our results showed the DHBAs also aug-
mented efficacy of AMB, in vitro, against yeast pathogens. Co-
application of DHBAs with AMB resulted in complete inhibition
of fungal growth at lower doses than any of the individual
components applied, alone. Based on gene deletion mutant
bioassays, it now appears that this synergy between AMB and
DHBAs is by targeting at least one common cellular compo-
nent in the antioxidant system, Mn-SOD. SODs of C. albicans
are involved in biofilm persistence against miconazole (Bink
et al., 2011), further demonstrating the role of fungal SODs in
drug resistance. The non-DHBAs tested were poor chemosensi-
tizing agents of AMB against yeast pathogens, indicating hydroxyl
(−OH) substituents on the aromatic ring contributed to improved
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antifungal/chemosensitizing activity. Of note is benzaldehydes
having ortho- and para-hydroxylation possessed higher antifun-
gal activity than meta- or mono-hydroxyl analogs (Kim et al.,
2008).
The results of this in vitro study demonstrate that chemically
targeting the oxidative stress response system of fungi effec-
tively augments antimycotic potency of AMB. DHBAs or their
analogs could be developed as potent chemosensitizers to AMB in
yeast pathogens. Chemosensitization by using natural compounds
could enhance the efficacy of AMB to inhibit fungal growth, and
lower the adverse side effects of AMB. Further in vivo studies are
needed to determine if the activities of chemosensitizers shown in
this in vitro study can translate to a clinically effective resolution
of mycoses.
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